ASH: Roche Looks To Fixed-Duration Edge In Bispecifics Battle

Roche is highlighting the fixed-duration dosing benefits of Lunsumio and Columvi over AbbVie/Genmab’s Epkinly in B-cell lymphomas as they fight for market dominance. However, the speed at which the companies complete Phase III studies could also be a deciding factor.

Roche_Logo_Glass

Roche is looking to Phase III clinical trial results to show its Lunsumio and Columvi are the best new bispecific therapies in B-cell lymphomas, and is also highlighting patient convenience and economics as it tries to get ahead of AbbVie/Genmab’s rival CD20XCD3-targeting bispecific, Epkinly.

The company is emphasizing the benefits of its approach of using a fixed duration of treatment with Lunsumio (mosunetuzumab) in...

More from ASH

More from Therapy Areas

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By 

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.